Every lot of GLP-2 / Cagri is tested by an independent ISO/IEC 17025-accredited lab in the USA. 99%+ purity isn't a target here. It's the requirement.
Don't take our word for it: test any vial at an accredited lab of your choice. If HPLC purity comes back under 99%, we refund your order and pay for the test.
This is a blend. GLP-2 and Cagri are combined in a single 10 mg vial, 5 mg of each. GLP-2 is a dual GIP/GLP-1 receptor research compound; Cagri is a long-acting amylin-analog research compound. The pairing places an incretin arm and an amylin arm in one vial. The combination itself has not been characterised as a single entity.
The numbers that define GLP-2 / Cagri and how it is being studied. For laboratory research use only.
2
Research Compounds
GLP-2 · Cagri
10 mg
Total Per Vial
5 mg of each component
2
Pathway Arms
Incretin · amylin
4
Research Areas
Satiety signalling
Glucose handling
Gastric emptying
How It Works
How GLP-2 / Cagri works
The pathways GLP-2 / Cagri acts on - and what each one does. The animation traces its signal outward from the compound to every target it engages.
Signalling pathways studied in preclinical models · illustrative
Dual Incretin Receptor Activity
GLP-2
Co-agonism at the GIP and GLP-1 receptors is characterised, with glucose-dependent insulin release as the primary measured readout.
GIP receptor engagement
GLP-1 receptor engagement
Gastric-emptying endpoints
Amylin Receptor Signalling
Cagri
Amylin analogs are characterised at the calcitonin and amylin receptor complexes, with satiety signalling and gastric-emptying rate as measured endpoints.
Amylin receptor complexes
Satiety signalling
Gastric-emptying rate
Parallel Pathway Coverage
Combined
The vial places an incretin arm and an amylin arm under matched handling. No interaction between the two has been characterised.
Two distinct pathways
Matched storage
Interaction not characterised
Uses & Applications
What GLP-2 / Cagri is researched for
The main areas GLP-2 / Cagri is being studied for - and the study-reported figures behind them.
Metabolic
Satiety Signalling Models
Amylin-analog literature measures satiety signalling and food-intake endpoints in preclinical models.
Metabolic
Glucose Handling
The incretin arm is studied for glucose-dependent insulin release.
Gastroenterology
Gastric Emptying
Both arms carry gastric-emptying endpoints in the published literature.
Methods
Parallel-Arm Protocols
One vial supports protocols that need both pathway arms under matched conditions.
Study-reported magnitudes
Representative figures from published research. Bars fill as you scroll.
Incretin Receptor EngagementCharacterised
Amylin Receptor SignallingCharacterised
Gastric-Emptying EndpointsMeasured
Blend Interaction DataNone
Figures are representative of published research findings and shown for reference.
Molecular Structure
The GLP-2 / Cagri molecule
An interactive 3D model rendered from the compound record - rotate and explore its structure.
Molecular model
Sequence length
blend
Physical form
Lyophilized powder blend
Documented purity
≥99% by HPLC
Compound Information
Full specification
Components
GLP-2 + Cagri
Content
10 mg per vial (5 mg of each component)
Pathways
Incretin (GIP/GLP-1) · amylin
Form
Lyophilized powder blend
Purity
≥99% by HPLC
Appearance
White to off-white powder
Solubility
Water-soluble
Storage
-20°C, protected from light
Classification
Research use only
FAQ
Common questions about GLP-2 / Cagri
They act through separate receptor systems. Holding both in one vial supports protocols that need an incretin arm and an amylin arm under matched handling.
No. Each compound is characterised separately. No interaction data exists for the pair.
Cagri is Eon's designation for the long-acting amylin-analog research compound sold individually as Cagri 10 mg.
Each lot is analysed by reverse-phase HPLC and released at ≥99%, with a Certificate of Analysis.
Store lyophilized at -20°C for long-term stability, protected from light and moisture, and avoid repeated freeze-thaw cycles.
Research Use Only.
Not for human or veterinary use. For in-vitro laboratory research only. These statements have not been evaluated by the FDA; this product is not intended to diagnose, treat, cure, or prevent any disease. Sold exclusively to qualified researchers and institutions.
